BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1400 related articles for article (PubMed ID: 11397861)

  • 1. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group.
    Hum Reprod; 2000 Jul; 15(7):1446-51. PubMed ID: 10875887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer.
    Chang P; Kenley S; Burns T; Denton G; Currie K; DeVane G; O'Dea L
    Fertil Steril; 2001 Jul; 76(1):67-74. PubMed ID: 11438321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization.
    Manau D; Fábregues F; Arroyo V; Jiménez W; Vanrell JA; Balasch J
    Fertil Steril; 2002 Dec; 78(6):1261-7. PubMed ID: 12477522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
    Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
    Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering final oocyte maturation with reduced doses of hCG in IVF/ICSI: a prospective, randomized and controlled study.
    Lin H; Wang W; Li Y; Chen X; Yang D; Zhang Q
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):143-7. PubMed ID: 21824709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles.
    Zelinski-Wooten MB; Hutchison JS; Chandrasekher YA; Wolf DP; Stouffer RL
    J Clin Endocrinol Metab; 1992 Aug; 75(2):502-7. PubMed ID: 1639951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
    Youssef MA; Abou-Setta AM; Lam WS
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003719. PubMed ID: 27106604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.
    J Clin Endocrinol Metab; 1998 May; 83(5):1507-14. PubMed ID: 9589647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Escudero EL; Boerrigter PJ; Bennink HJ; Epifanio R; Horcajadas JA; Olivennes F; Pellicer A; Simón C
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2081-8. PubMed ID: 15483085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization.
    Kovacs P; Kovats T; Bernard A; Zadori J; Szmatona G; Kaali SG
    Fertil Steril; 2008 Dec; 90(6):2133-7. PubMed ID: 18177866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.